Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients

dc.contributor.authorQuintairos Domenech, Luis
dc.contributor.authorColom Codina, Helena
dc.contributor.authorMillán, Olga
dc.contributor.authorFortuna, Virginia
dc.contributor.authorEspinosa, Cristina
dc.contributor.authorGuirado, Lluís
dc.contributor.authorBudde, Klemens
dc.contributor.authorSommerer, Claudia
dc.contributor.authorLizana, Ana
dc.contributor.authorLópez Púa, Yolanda
dc.contributor.authorBrunet i Serra, Mercè
dc.date.accessioned2021-03-23T10:12:53Z
dc.date.available2021-03-23T10:12:53Z
dc.date.issued2021-01-22
dc.date.updated2021-03-23T10:12:53Z
dc.description.abstractPrevious results from our group and others have shown that urinary pellet expression of miR155-5p and urinary CXCL-10 production could play a key role in the prognosis and diagnosis of acute rejection (AR) in kidney transplantation patients. Here, a logistic regression model was developed using NONMEM to quantify the relationships of miR155-5p urinary expression, CXCL-10 urinary concentration and tacrolimus and mycophenolic acid (MPA) exposure with the probability of AR in adult kidney transplant patients during the early post-transplant period. Owing to the contribution of therapeutic drug monitoring to achieving target exposure, neither tacrolimus nor MPA cumulative exposure was identified as a predictor of AR in the studied population. Even though CXCL-10 urinary concentration showed a trend, its effect on AR was not significant. In contrast, urinary miR155-5p expression was prognostic of clinical outcome. Monitoring miR155-5p urinary pellet expression together with immunosuppressive drug exposure could be very useful during routine clinical practice to identify patients with a potential high risk of rejection at the early stages of the post-transplant period. This early risk assessment would allow for the optimization of treatment and improved prevention of AR.
dc.format.extent20 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec707394
dc.identifier.issn1932-6203
dc.identifier.pmid33481955
dc.identifier.urihttps://hdl.handle.net/2445/175587
dc.language.isoeng
dc.publisherPublic Library of Science (PLoS)
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1371/journal.pone.0245880
dc.relation.ispartofPLoS One, 2021, vol. 16, num. 1, p. e0245880
dc.relation.urihttps://doi.org/10.1371/journal.pone.0245880
dc.rightscc-by (c) Quintairos, Lluís et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationMarcadors bioquímics
dc.subject.classificationFarmacocinètica
dc.subject.classificationTrasplantament renal
dc.subject.classificationFactors de risc en les malalties
dc.subject.otherBiochemical markers
dc.subject.otherPharmacokinetics
dc.subject.otherKidney transplantation
dc.subject.otherRisk factors in diseases
dc.titleEarly prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
707394.pdf
Mida:
1.28 MB
Format:
Adobe Portable Document Format